Low iron can cause high cholesterol, but only through specific indirect pathways rather than a single direct switch. Iron deficiency raises LDL cholesterol modestly in some people by suppressing thyroid hormone conversion, impairing hepatic lipid clearance, and triggering compensatory metabolic shifts. The effect is real but usually small, typically 5 to 15 percent above baseline LDL, and it is far more likely to matter in iron deficiency anemia than in isolated low ferritin. For most adults, low iron is a contributing factor to a cholesterol panel change, not the primary cause of clinical hypercholesterolemia.
The mechanism: how iron status reaches the lipid panel
Iron is a cofactor for two hepatic enzymes that sit upstream of cholesterol handling: thyroid peroxidase and the deiodinases that convert thyroxine (T4) into triiodothyronine (T3). When iron stores fall, T4-to-T3 conversion drops. The liver then shifts toward a hypothyroid-like state even when TSH looks normal, and hepatic LDL receptor expression falls with it. Fewer LDL receptors means less LDL pulled out of circulation, so serum LDL rises.
The second pathway is mitochondrial. Iron is required for the electron transport chain and for the activity of carnitine palmitoyltransferase. When iron is scarce, hepatocytes rely more heavily on de novo cholesterol synthesis and less on fatty acid oxidation. The net effect is a small increase in hepatic cholesterol output at the same time clearance is impaired.
The third pathway is hormonal and stress-related. Iron deficiency raises erythropoietin drive and sympathetic tone, which increases circulating free fatty acids. The liver packages these into VLDL, and VLDL is the precursor to LDL. In plain terms: the body responds to low iron by making more cholesterol-carrying vehicles while clearing fewer of them.
None of these pathways is a linear switch. The magnitude depends on how low iron goes, how long it stays low, and whether thyroid function was already borderline. That dependency is why studies show consistent direction but inconsistent size.
Quantified context: how large is the effect?
The strongest human data come from iron deficiency anemia cohorts and from iron repletion trials. In observational studies of adults with iron deficiency anemia, mean LDL cholesterol runs roughly 10 to 20 mg/dL higher than matched controls, with total cholesterol 8 to 30 mg/dL higher. Reversal after successful iron therapy is partial and slow.
| Parameter | Before iron repletion | After 3-6 months | Magnitude |
|---|---|---|---|
| LDL cholesterol | 130-160 mg/dL | 115-145 mg/dL | Down 8-20 mg/dL |
| Total cholesterol | 200-230 mg/dL | 185-215 mg/dL | Down 10-25 mg/dL |
| HDL cholesterol | 45-55 mg/dL | 48-58 mg/dL | Up 2-6 mg/dL |
| Triglycerides | 140-190 mg/dL | 125-170 mg/dL | Down 10-25 mg/dL |
| Ferritin | under 30 ng/mL | 50-150 ng/mL | Reference shift |
| TSH (if measured) | 1.5-3.5 mIU/L | 1.0-2.5 mIU/L | Slight fall |
These are pooled ranges from small interventional studies, not a single trial, and the spread reflects genuine heterogeneity. The effect is smaller than a statin (which lowers LDL 30 to 50 percent) and smaller than dietary saturated fat changes of 10 percent of calories (which move LDL 10 to 15 mg/dL). So the practical framing matters: low iron is a lever, not the lever.
A useful comparison not often stated: correcting iron deficiency anemia moves LDL roughly as much as adding 5 to 10 grams of soluble fiber per day, but far less than reducing saturated fat by 5 percent of total calories.
Variations and edge cases
Not everyone with low iron gets a lipid shift. The phenotype matters.
Iron deficiency without anemia, ferritin under 30 ng/mL but normal hemoglobin, produces inconsistent lipid changes, often under 5 mg/dL. Iron deficiency anemia, hemoglobin under 12 g/dL in women or 13 g/dL in men, produces the larger shifts described above. Hereditary hemochromatosis, the opposite problem, is associated with lower LDL and higher HDL in many cohorts, which supports the idea that iron status sits on a continuum affecting lipids in both directions.
Hypothyroidism is the confounder that matters most. Overt hypothyroidism raises LDL 20 to 50 mg/dL and also lowers ferritin absorption. When both are present, treating thyroid disease alone often normalizes the panel, and iron repletion adds little. The reverse is also true: in subclinical hypothyroidism, iron deficiency can push a borderline panel over a treatment threshold.
Pregnancy is its own case. Iron demands rise 50 percent or more, and LDL rises physiologically by 30 to 50 percent in the second and third trimesters. Attributing that rise to iron deficiency is a common error; it is expected physiology and resolves postpartum.
Timeline: what changes when, after iron repletion
| Time since starting iron | Hemoglobin | Ferritin | LDL cholesterol |
|---|---|---|---|
| Week 1-2 | Unchanged to +0.5 g/dL | Unchanged | No measurable change |
| Week 3-4 | +1.0 to +2.0 g/dL | Slight rise | Small fall begins |
| Month 2-3 | Near normal | 30-60 ng/mL | 5-10 mg/dL lower typical |
| Month 4-6 | Normal | 50-100 ng/mL | Full effect, 8-20 mg/dL lower |
| Month 6-12 | Normal | 80-150 ng/mL | Stable |
| After stopping iron | May fall if cause persists | Falls over months | Reverses with iron status |
The lesson from this timeline: a repeat lipid panel drawn two weeks after starting iron pills tells you nothing about the iron-lipid relationship. Wait at least three months, ideally after ferritin normalizes.
Common misconceptions, corrected
The first misconception is that low iron directly raises cholesterol the way a drug does. Iron is a cofactor, not a lipid-regulating hormone. The relationship is conditional and modest.
The second is that iron supplements lower cholesterol. In people with normal iron stores, iron supplementation does not lower LDL and may slightly raise oxidative stress markers. The lipid benefit appears only in the deficient.
The third is that all anemia affects lipids the same way. Anemia of chronic inflammation, common in kidney disease and autoimmune disease, often lowers LDL rather than raising it, because inflammatory cytokines suppress hepatic cholesterol synthesis. That is the opposite direction from iron deficiency anemia, and the two look identical on a basic complete blood count.
The fourth, and the most consequential in practice, is treating a high LDL found alongside low ferritin as purely an iron problem. If LDL is 190 mg/dL, iron repletion will not bring it to goal, and delay in lipid-lowering therapy carries real cardiovascular risk. In plain terms: fix the iron, but do not let it become an excuse to ignore a high LDL.
What to actually do
Get the right labs before drawing conclusions. A ferritin plus a complete blood count plus a lipid panel drawn at the same visit lets you see the relationship directly. Ferritin under 30 ng/mL defines iron deficiency in most guidelines; ferritin under 15 ng/mL is more specific. Add TSH if the lipid panel is abnormal, because thyroid disease is the higher-yield explanation.
Treat the cause of the iron deficiency, not just the number. Menstrual blood loss, gastrointestinal bleeding, celiac disease, and low dietary intake are the common drivers, and each has a different fix. In adults over 45 with new iron deficiency anemia, gastrointestinal evaluation is standard because the prevalence of occult bleeding lesions is meaningful.
Recheck lipids three to six months after ferritin normalizes, not sooner. If LDL remains above goal after iron is corrected, treat the LDL on its own merits per the 2018 ACC/AHA cholesterol guidelines, which base statin decisions on calculated 10-year atherosclerotic cardiovascular disease risk rather than on iron status.
Use food first where possible. Heme iron from meat, poultry, and fish absorbs at 15 to 35 percent; non-heme iron from legumes and fortified cereals absorbs at 2 to 20 percent and improves with vitamin C taken at the same meal. Coffee and tea within an hour of an iron-rich meal cut absorption by 30 to 60 percent.
Red flags that change the plan
- LDL of 190 mg/dL or higher at any age, which suggests familial hypercholesterolemia rather than an iron effect.
- Iron deficiency anemia in a man or a postmenopausal woman, which warrants gastrointestinal evaluation.
- Ferritin under 15 ng/mL with normal hemoglobin and no obvious blood loss, which may indicate malabsorption.
- A lipid panel that worsens despite normalizing ferritin, which points to a primary lipid disorder.
- Symptoms of hypothyroidism, including fatigue, cold intolerance, and constipation, alongside low iron.
Limitations of the evidence
The iron-lipid literature is built mostly on small observational cohorts and short repletion trials, typically 20 to 100 participants, with heterogeneous definitions of deficiency. No large randomized trial has tested whether correcting iron deficiency lowers cardiovascular events, and none is likely soon. The mechanistic pathways are plausible and partially demonstrated in animal models, but the human effect size remains uncertain within the 5 to 20 mg/dL range described here.
It is also worth being explicit about what is established versus hypothesized. That iron deficiency anemia is associated with higher LDL and triglycerides is established across multiple cohorts. That iron repletion reliably lowers LDL by a specific amount is supported but not proven at scale. That correcting iron reduces heart attacks is hypothesis only, with no trial evidence.
Numbers in this article are reconciled as follows: ferritin under 30 ng/mL defines deficiency, under 15 ng/mL is more specific, and the 5 to 20 mg/dL LDL effect described throughout applies to the anemic range (hemoglobin under 12 g/dL in women, under 13 g/dL in men), with smaller effects of under 5 mg/dL in deficiency without anemia. The practical takeaway holds either way: low iron can nudge cholesterol upward, correcting it can nudge cholesterol back down, and neither replaces standard cardiovascular risk assessment.